<unk>  is a vesicular monoamine transporter 2 (VMAT2) inhibitor that is FDA approved for the treatment of chorea associated with Huntington’s disease, and tardive dyskinesia. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include somnolence, diarrhea, dry mouth, fatigue, nasopharyngitis, and insomnia.
Deutetrabenazine
Selegiline 
Rasagiline
Tetrabenazine
Rimonabant
Thioridazine hydrochloride
Bedaquiline fumarate
Retigabine